Pricing
Drug Pricing Will Be a Key Issue, Whether Clinton or Trump Win the Election
September 22, 2016Policymakers respond to a crisis and every crisis has to have a villain. Unfortunately, today pharma is the villain.
McCann Health forms new global consultancy
September 22, 2016The consultancy includes Double Helix, which was acquired by McCann in 2012.
Five things for pharma marketers to know: Monday, September 19, 2016
September 19, 2016Some U.S. hospitals still haven't received Valeant discounts; U.N. General Assembly will discuss antibiotic resistance; AstraZeneca diabetes drugs lowered blood sugar in study
Five things for pharma marketers to know: Thursday, September 15, 2016
September 15, 2016Mylan CEO to appear before House committee about EpiPen pricing; job-related health premiums rise; GSK's experimental shingles vaccine shows 90% effectiveness
Five things for pharma marketers to know: Wednesday, September 7, 2016
September 07, 2016BIO launches ad campaign defending drugmakers; GSK's experimental COPD drug reduces flare-ups in patients; NY attorney general to investigate Mylan
CEO: Allergan will limit price increases for branded drugs
September 07, 2016CEO Brent Saunders also said the drugmaker will not increase the price of drugs nearing patent expiration.
Mylan's branded ad spending on the EpiPen rose 357% — to $43 million in 2015 — over five years
August 31, 2016In 2011 the drugmaker spent $9.4 million on branded ads for the EpiPen. By 2015, branded ad spending hit $43 million.
Five things for pharma marketers to know: Monday, August 29, 2016
August 29, 2016Mylan to launch generic EpiPen; the majority of NCCN guideline writers report conflicts of interest; Sanofi reports new trial data for Praluent
Five things for pharma marketers to know: Friday, August 26, 2016
August 26, 2016Sarah Jessica Parker cuts ties with Mylan over pricing controversy; lung-cancer physicians turn to Keytruda; Merck KGaA diversifies its business
Five things for pharma marketers to know: Thursday, August 25, 2016
August 25, 2016Mylan offers additional copay assistance for EpiPen amid criticism; fewer doctors are seeing reps; two Copaxone patents are invalidated
Five things for pharma marketers to know: Wednesday, August 24, 2016
August 24, 2016Retzlaff files a complaint against Turing; Pfizer to buy antibiotics from AstraZeneca; Mylan's marketing for EpiPen faces criticism
PBMs push forward toward outcomes-based pricing, despite challenges
August 07, 2016The implementation of a broad outcomes-based pricing scheme is a wildly, almost gratuitously complicated project.
Five things for pharma marketers to know: Friday, July 29, 2016
July 29, 2016England's NHS delays hep-C coverage due to pricing; Google reports 21% revenue growth; U.S. and U.K. announce partnership for antibiotic development
Five things for pharma marketers to know: Thursday, July 21, 2016
July 21, 2016The FDA approves generic versions of AstraZeneca's Crestor; Biogen CEO steps down; drugmakers race to develop smart inhalers
Five things for pharma marketers to know: Thursday, July 7, 2016
July 07, 2016EpiPen price hikes led to syringe use; states with medical marijuana laws have drops in drug spending; Pfizer and Merck KGaA start ovarian cancer trial
Five things for pharma marketers to know: Tuesday, June 7, 2016
June 07, 2016Gilead CEO talks drug pricing; multiple-sclerosis drugmakers study the overall cost of care; Biden launches national cancer database
Five things for pharma marketers to know: Monday, June 6, 2016
June 06, 2016Researchers question cost of multiple-myeloma combo; drugmakers say CAR-T therapies will soon be approved; the FDA approves Allergan's hypertension drug
Five things for pharma marketers to know: Wednesday, June 1, 2016
June 01, 2016WHO finds poor countries are paying too much for HCV drugs; Gilead faces a lawsuit over an HIV drug; BioMarin to stop developing Duchenne treatment
Five things for pharma marketers to know: Thursday, May 12, 2016
May 12, 2016Valeant has not delivered promised price breaks on heart drugs; AstraZeneca drug receives orphan status; Allergan promotes Meury and Stewart
Reframing the Debate: Why Drug Spending Can Lower Costs
May 04, 2016Rising healthcare costs, coupled with high-profile stories of price gouging at some small pharmaceutical companies, have left consumers feeling ripped off
Spending on drugs is up, but by how much?
May 02, 2016Total medicine spending surged to $424.8 billion in 2015, representing an increase of 12.2%. Here's why that growth figure is closer to 2.9%.
Five things for pharma marketers to know: Wednesday, April 27, 2016
April 27, 2016Pearson expected to say price hikes were too aggressive; Collegium's painkiller receives full FDA approval; most hospitals stop advertising infant formula
Zika Crisis Stresses Need for Pharma Industry
April 22, 2016When pharmaceutical companies are needed, we're Jonas Salks; when we ask to be paid, we're Martin Shkrelis.
Five things for pharma marketers to know: Thursday, April 14, 2016
April 14, 2016Government identifies barriers to eliminating hepatitis C; Pearson agrees to congressional deposition; CMS reportedly plans to revoke Theranos license
Five things for pharma marketers to know: Tuesday, April 12, 2016
April 12, 2016California bill would require price disclosures; AbbVie's and Genentech's blood-cancer drug is approved; FDA expands metformin use
Amgen takes issue with yet-to-be published multiple-myeloma drug report
April 05, 2016The drugmaker instead suggested using an economic model it developed.
Five things for pharma marketers to know: Friday, April 1, 2016
April 01, 2016GSK won't patent drugs sold in low-income countries; experimental dermatitis therapy met Phase III endpoints; the FDA issues biosimilar labeling guidance
Another physician group raises concerns about DTC
March 30, 2016The American College of Physicians questioned the role direct-to-consumer advertising plays in contributing to prescription drug costs.
Five things for pharma marketers to know: Monday, March 21, 2016
March 21, 2016Pearson to be replaced at Valeant; Pfizer's Xeljanz meets Phase III goals; Harvard partners with Merck on leukemia drug development
Five things for pharma marketers to know: Friday, March 18, 2016
March 18, 2016OptumRx partners with Walgreens Boots Alliance; Turing's former lawyer said Daraprim price hike was unjustified; the White House names moonshot leader
MM&M Articles
- McCann Health forms new global consultancy
- Alexion uses superheroes, social media to raise rare-disease awareness
- Five things for pharma marketers to know: Tuesday, September 20, 2016
- Five things for pharma marketers to know: Wednesday, September 21, 2016
- Five things for pharma marketers to know: Monday, September 19, 2016
- Merck educates doctors about biosimilars, long before it will sell one in the U.S.
- 4 trends with the potential to change behavior in the patient journey
- When it comes to professional ads, print makes its comeback
- 2016 Pharma Report: All the data in one place
- What do physicians think about biosimilars?
- The FDA approves Amgen's biosimilar version of Humira
- Five things for pharma marketers to know: Friday, September 23, 2016
- Five things for pharma marketers to know: Thursday, September 22, 2016
- Drug Pricing Will Be a Key Issue, Whether Clinton or Trump Win the Election
- The Michael J. Fox Foundation uses Facebook to recruit Ashkenazi Jews for Parkinson's study
